Last mentioned: Mar 9, 2026
DCAT Week 2026
LOTTE Biologics engages in high-level partnership talks in New York City.
ADC Expansion
Completion of specialized ADC manufacturing lines at the Syracuse facility.
Songdo Groundbreaking
Construction begins on the first Mega Plant in Songdo, South Korea.
Syracuse Acquisition
LOTTE Biologics completes the acquisition of the Syracuse, NY plant from Bristol Myers Squibb.
LOTTE Biologics is set to engage with global pharmaceutical leaders at DCAT Week 2026 in New York, aiming to secure strategic partnerships and showcase its expanding CDMO capabilities. The move underscores the company's aggressive push to become a top-tier global contract manufacturer by leveraging its Syracuse and Songdo facilities.
LOTTE Biologics is attending DCAT Week 2026 in New York to secure high-value global partnerships and solidify its position in the CDMO market. This move underscores the company's aggressive strategy to leverage its U.S. manufacturing footprint and upcoming South Korean capacity.